Saudi Arabia is emerging as a major growth market for clinical trials in the Middle East, underpinned by strong funding and rapidly developing infrastructure.

BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.

Estimates suggest fragmented technology can raise clinical trial costs by 45%, but a unified approach to clinical data management can enable efficiency.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

Chiesi said the KalVista deal will bolster Chiesi Global Rare Diseases, it’s business unit marketing therapies in the sector. Credit: Na_Studio/Shutterstock.com. Chiesi has conducted the largest ...

Teva’s Emalex buyout falls under the company's wider strategy of prioritising deals around de-risked, differentiated, late-stage assets.

The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...

Regeneron raised GAAP gross margin on net product sales to 79% to 80% from 77% to 78%. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Source is increasing in appeal across clinical research, offering sites and sponsors greater efficiencies in resources as budgets tighten, along with higher levels of precision and quality in data ...